文献速递心力衰竭与心肌病心律失常

房颤节律控制后射血分数正常化时停用心衰药物:WITHDRAW-AF试验

Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial.
PubMed 文献 · Eur Heart J · 2026-01-01

WITHDRAW-AF是一项多中心随机交叉试验,纳入60例房颤相关心肌病房颤节律控制后LVEF恢复正常的患者,随机分为早期停用心衰药物组(A组)和继续用药6个月后延迟停药组(B组)。结论认为多数患者停用心衰药物后6个月内LVEF未见下降。

要点

  • 房颤相关心肌病患者节律控制后LVEF恢复,停用心衰药物6个月内90%维持LVEF≥50%。
  • 超声、NT-proBNP、功能状态、生活质量及房颤负荷在停药与用药期间相似。

核心结论

  • 房颤相关心肌病患者经节律控制、LVEF恢复后停用心衰药物,多数患者6个月内LVEF未见下降。

研究设计与样本

  • 多中心随机交叉试验,2021至2024年纳入60例房颤相关心肌病患者,随机1:1分为早期停药组(A组)和继续用药6个月后延迟停药组(B组),随访12个月。

临床怎么用

  • 对于房颤相关心肌病经节律控制后LVEF恢复正常的患者,可考虑在密切监测下停用心衰药物。

局限性

  • 样本量较小(60例),主要终点事件数少,置信区间宽,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Atrial fibrillation-mediated cardiomyopathy (AFCM) represents an important reversible cause of left ventricular systolic dysfunction. Current clinical practice is indefinite heart failure (HF) pharmacotherapy despite left ventricular ejection fraction (LVEF) normalization. However, whether this is necessary to maintain normal LVEF, in addition to rhythm control, is uncertain. METHODS: This multi-centre, randomized trial conducted between 2021 and 2024 examined the impact of staged withdrawal of HF therapy following AF rhythm control and LVEF normalization in AFCM. Participants were randomized (1:1) to early withdrawal (Group A) or continued therapy for 6 months followed by delayed withdrawal (Group B), in a crossover design. The primary endpoint was the randomized comparison of cardiac magnetic resonance (CMR) LVEF maintenance ≥50% at 6 months, during which time Group A had withdrawn therapy and Group B remained on treatment. Secondary outcomes included cardiac remodelling, functional status, biomarkers, quality of life, and arrhythmia recurrence on vs off HF therapy. The total follow-up duration was 12 months. RESULTS: Between July 2021 and May 2024, 60 patients were enrolled (age 60 [55-65] years, previous persistent AF <1 year and maintaining sinus rhythm for minimum 6 months following AF rhythm control [catheter ablation in 97%]). All participants completed treatment withdrawal and 12-month follow-up. In the initial randomized comparison, LVEF was maintained ≥50% at 6 months in 90% of participants undergoing HF therapy withdrawal (Group A), compared with 100% who continued medical therapy (Group B) (odds ratio [OR] 1.18, 95% confidence interval [CI] 0.27-2.82, P = .47). CMR LVEF was similar between randomization groups at the end of the randomization phase (Group A: LVEF 58% [95% CI 54-60] vs Group B: LVEF 59% [95% CI 55-64], P = .236) and across study time points (mixed effects P = .37). Transthoracic echocardiography characteristics, N-terminal pro-B-type natriuretic peptide, functional status, quality of life and AF burden were similar on vs off HF therapy in the overall population. CONCLUSIONS: Withdrawal of HF therapy following AF rhythm control for prior AFCM and recovered LVEF was not associated with a decline in LVEF for most patients in the following 6 months.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Segan, Kistler, Nanayakkara, et al. Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial. Eur Heart J. 2026. PMID: 40830055. doi:10.1093/eurheartj/ehaf563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。